The FDA announced the approval of drug that can treat cancer Vitrakvi is a targeted therapy designed to treat specific types of solid tumors that carry a genetic mutation known as NTRK.
The photo of Vitrakvi.
Claim: Vitrakvi is a miracle drug that cures all types of cancer.
Cancer is considered one of the main causes of death, and it affects people of all ages due to various genetic changes that ultimately lead to the cell losing control over growth and division, causing excessive division and tumors to form. Rumors abound about the existence of curative treatments for it, the most prominent of which during this period was the claim that one of the anti-tumor drugs under development is a cure for cancer of all types and regardless of its location.
In November 26, 2018 social media users began talk the US Food and Drug Administration (FDA) announced the approval of the first drug in the world that can treat cancer from its source and origin, for adults and children, according to what the commissioner of the government agency said. The drug “Vitrakvi” relies on treating genetic mutations in cancerous tumors, regardless of the type of disease or its place of origin. The new drug will help cancer patients obtain the appropriate treatment, and the drug “Vitrakvi” contributes to the treatment of people who suffer from different cancerous tumors, but who possess common genetic mutations. Traditionally, cancer was treated based on the source of the cancerous tumor, but now the treatment will be anywhere in the body because you are treating the original gene that caused the tumor
to appear. The drug was actually tried on humans, and the case of recovery of a child was recorded within months after taking the drug, and the drug will be offered on two bodies, the first in the form of tablets or capsules, and the other in the form of a syrup for children in particular.
But this news is partly false.
The drug Vitrakvi is not a magic drug that kills cancer in all its forms and stages. The drug Vitrakvi is the second drug that treats tumors that carry a specific genetic characteristic. It is a specialized drug for treating solid cancerous tumors that carry the NTRK genetic factor. The drug is for specific types that can spread and cannot be removed surgically. This drug is considered promising and important in that it is directed to a specific area in which the production of the NTRK gene increases, and it will be available to adults and children whose tumors carry this genetic factor. Not all tumors responded to treatment. The tumors that responded to the drug at a rate of 39% were sarcoma, salivary gland tumor, thyroid cancer, lung cancer, and infantile fibrosarcoma. This medication also had some common side effects that were not mentioned, such as fatigue, nausea, vomiting, cough, constipation, diarrhea, and dizziness. It is necessary to have a periodic blood test to check liver function, and pregnant and breastfeeding women are not allowed to take it. This treatment is used to treat specific cases and not all tumors. The Saudi Food and Drug Authority made a clarification regarding this drug.
Clarification from the Food and Drug Administration from its official page on X
Sources:
https://www.cancer.org/cancer/managing-cancer/treatment-types/tumor-agnostic drugs.html
https://www.moh.gov.sa/Ministry/MediaCenter/News/Pages/News-2018-11-29- 007.aspx
ةزاجإ – حرط – لوأ – ءاود – جلاعی – ناطرسلا – ھعبنم /1203825–technology/com.skynewsarabia.www://https و ھلصأ
/ يفكارتیف – لوأ – ءاود – يضقی – ىلع – ناطرسلا /com.alseyassah://https
https://www.fda.gov/news-events/press-announcements/fda-approves-oncology-drug targets-key-genetic-driver-cancer-rather-specific-type-tumor
https://x.com/saudi_fda/status/1068522102636986368?s=48&prefetchTimestamp=1734 334899971
Trustify 